Removal of Soluble Fms-Like Tyrosine Kinase-1 by Dextran Sulfate Apheresis in Preeclampsia
Open accessThe DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Abstract
Preeclampsia is a devastating complication of pregnancy. Soluble Fms-like tyrosine kinase-1 (sFlt-1) is an antiangiogenic protein believed to mediate the signs and symptoms of preeclampsia. We conducted an open pilot study to evaluate the safety and potential efficacy of therapeutic apheresis with a plasma-specific dextran sulfate column to remove circulating sFlt-1 in 11 pregnant women (20-38 years of age) with very preterm preeclampsia (23-32 weeks of gestation, systolic BP ≥140 mmHg or diastolic BP ≥90 mmHg, new onset protein/creatinine ratio >0.30 g/g, and sFlt-1/placental growth factor ratio >85). We evaluated the extent of sFlt-1 removal, proteinuria reduction, pregnancy continuation, and neonatal and fetal safety of apheresis after one (n=6), two (n=4), or three (n=1) apheresis treatments. Mean sFlt-1 levels were reduced by 18% (range 7%-28%) with concomitant reductions of 44% in protein/creatinine ratios. Pregnancy continued for 8 days (range 2-11) and 15 days (range 11-21) in women treated once and multiple times, respectively, compared with 3 days (range 0-14) in untreated contemporaneous preeclampsia controls (n=22). Transient maternal BP reduction during apheresis was managed by withholding pre-apheresis antihypertensive therapy, saline prehydration, and reducing blood flow through the apheresis column. Compared with infants born prematurely to untreated women with and without preeclampsia (n=22 per group), no adverse effects of apheresis were observed. In conclusion, therapeutic apheresis reduced circulating sFlt-1 and proteinuria in women with very preterm preeclampsia and appeared to prolong pregnancy without major adverse maternal or fetal consequences. A controlled trial is warranted to confirm these findings.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Maynard, S. E., Min, J.-Y., Merchan, J., Lim, K.-H., Li, J., Mondal, S., Libermann, T. A., Morgan, J. P., Sellke, F. W., Stillman, I. E., et al. (2003) · Journal of Clinical Investigation · doi:10.1172/jci17189 · Cited by 4,101
Self-citationCirculating angiogenic factors and the risk of preeclampsia
Levine, R. J., Maynard, S. E., Qian, C., Lim, K.-H., England, L. J., Yu, K. F., Schisterman, E. F., Thadhani, R., Sachs, B. P., Epstein, F. H., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa031884 · Cited by 3,720
Self-citationCirculating angiogenic factors and the risk of preeclampsia*
(2004) · Obstetrics & Gynecology · doi:10.1097/00006250-200405000-00028 · Cited by 2,615
Kassebaum, N. J., Bertozzi-Villa, A., Coggeshall, M. S., Shackelford, K. A., Steiner, C., Heuton, K. R., Gonzalez-Medina, D., Barber, R., Huynh, C., Dicker, D., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60696-6 · Cited by 1,644
Cardiovascular sequelae of preeclampsia/eclampsia: A systematic review and meta-analyses
McDonald, S. D., Malinowski, A., Zhou, Q., Yusuf, S., & Devereaux, P. J. (2008) · American Heart Journal · doi:10.1016/j.ahj.2008.06.042 · Cited by 924
Antihypertensive drug therapy for mild to moderate hypertension during pregnancy
Abalos, E., Duley, L., & Steyn, D. W. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002252.pub3 · Cited by 705
Angiogenic factors and the risk of adverse outcomes in women with suspected preeclampsia
Rana, S., Powe, C. E., Salahuddin, S., Verlohren, S., Perschel, F. H., Levine, R. J., Lim, K.-H., Wenger, J. B., Thadhani, R., & Karumanchi, S. A. (2012) · Circulation · doi:10.1161/circulationaha.111.054361 · Cited by 668
Sugimoto, H., Hamano, Y., Charytan, D., Cosgrove, D., Kieran, M., Sudhakar, A., & Kalluri, R. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.c300012200 · Cited by 538
Walker, J. J. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02800-2 · Cited by 522
Sibai, B. M., Mercer, B. M., Schiff, E., & Friedman, S. A. (1994) · American Journal of Obstetrics and Gynecology · doi:10.1016/0002-9378(94)90104-x · Cited by 458
Cited by
Rana (2019) · doi:10.1161/circresaha.118.313276 · Cited by 2,095
Pre-eclampsia: pathophysiology and clinical implications
Burton, G. J., Redman, C. W., Roberts, J. M., & Moffett, A. (2019) · BMJ · doi:10.1136/bmj.l2381 · Cited by 1,250
Pre-eclampsia: pathogenesis, novel diagnostics and therapies
Phipps, E. A., Thadhani, R., Benzing, T., & Karumanchi, S. A. (2019) · Nature Reviews Nephrology · doi:10.1038/s41581-019-0119-6 · Cited by 1,191
Self-citationChappell, L. C., Cluver, C. A., Kingdom, J., & Tong, S. (2021) · The Lancet · doi:10.1016/s0140-6736(20)32335-7 · Cited by 925
Connelly‐Smith, L., Alquist, C. R., Aqui, N. A., Hofmann, J. C., Klingel, R., Onwuemene, O. A., Patriquin, C. J., Pham, H. P., Sanchez, A. P., Schneiderman, J., et al. (2023) · Journal of Clinical Apheresis · doi:10.1002/jca.22043 · Cited by 684
Preeclampsia: Updates in Pathogenesis, Definitions, and Guidelines
Phipps, E., Prasanna, D., Brima, W., & Jim, B. (2016) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.12081115 · Cited by 622
Endothelium structure and function in kidney health and disease
Jourde-Chiche, N., Fakhouri, F., Dou, L., Bellien, J., Burtey, S., Frimat, M., Jarrot, P.-A., Kaplanski, G., Le Quintrec, M., Pernin, V., et al. (2019) · Nature Reviews Nephrology · doi:10.1038/s41581-018-0098-z · Cited by 493
Biology and therapeutic targeting of vascular endothelial growth factor A
Pérez-Gutiérrez, L., & Ferrara, N. (2023) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-023-00631-w · Cited by 484
Preeclampsia: Risk Factors, Diagnosis, Management, and the Cardiovascular Impact on the Offspring
Fox, R., Kitt, J., Leeson, P., Aye, C. Y. L., & Lewandowski, A. J. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8101625 · Cited by 440
Arany, Z., & Elkayam, U. (2016) · Circulation · doi:10.1161/circulationaha.115.020491 · Cited by 403
Tracking placental development in health and disease
Aplin, J. D., Myers, J. E., Timms, K., & Westwood, M. (2020) · Nature Reviews Endocrinology · doi:10.1038/s41574-020-0372-6 · Cited by 374
Placental growth factor and pre-eclampsia
Chau, K., Hennessy, A., & Makris, A. (2017) · Journal of Human Hypertension · doi:10.1038/jhh.2017.61 · Cited by 352
Rana, S., Burke, S. D., & Karumanchi, S. A. (2022) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2020.10.022 · Cited by 335
Self-citationPreeclampsia beyond pregnancy: long-term consequences for mother and child
Turbeville, H. R., & Sasser, J. M. (2020) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00071.2020 · Cited by 306
Matrix Metalloproteinases in Normal Pregnancy and Preeclampsia
Chen, J., & Khalil, R. A. (2017) · Progress in Molecular Biology and Translational Science · doi:10.1016/bs.pmbts.2017.04.001 · Cited by 274
Angiogenic Factors in Preeclampsia: From Diagnosis to Therapy
Karumanchi, S. A. (2016) · Hypertension · doi:10.1161/hypertensionaha.116.06421 · Cited by 163
Self-citationSequential plasma angiogenic factors levels in women with suspected preeclampsia
Baltajian, K., Bajracharya, S., Salahuddin, S., Berg, A. H., Geahchan, C., Wenger, J. B., Thadhani, R., Karumanchi, S. A., & Rana, S. (2016) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2016.01.168 · Cited by 88
Self-citationPadmanabhan, S., Lee, V. W., Mclean, M., Athayde, N., Lanzarone, V., Khoshnow, Q., Peek, M. J., & Cheung, N. W. (2017) · Diabetes Care · doi:10.2337/dc17-0391 · Cited by 55
Placental Drug Delivery to Treat Pre‐Eclampsia and Fetal Growth Restriction
Deepak, V., El‐Balawi, L., & Harris, L. K. (2024) · Small · doi:10.1002/smll.202311165 · Cited by 16
Metadata
- Authors
- Thadhani, R., Hagmann, H., Schaarschmidt, W., Roth, B., Cingoez, T., Karumanchi, S. A., Wenger, J., Lucchesi, K. J., Tamez, H., Lindner, T., Fridman, A., Thome, U., Kribs, A., Danner, M., Hamacher, S., Mallmann, P., Stepan, H., & Benzing, T.
- Venue
- Journal of the American Society of Nephrology
- Published
- 2016-03
- Volume
- 27
- Issue
- 3
- Pages
- 903-913
- ISSN
- 1046-6673 (ISSN-L)
- OpenAlex
- W2185931826
- Cited by
- 278
- References
- 38
- FWCI
- 32.42
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.